1. Home
  2. GERN vs CAC Comparison

GERN vs CAC Comparison

Compare GERN & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

SELL

Current Price

$1.17

Market Cap

1.0B

Sector

Health Care

ML Signal

SELL

Logo Camden National Corporation

CAC

Camden National Corporation

SELL

Current Price

$56.15

Market Cap

923.2M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
GERN
CAC
Founded
1990
1875
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
923.2M
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
GERN
CAC
Price
$1.17
$56.15
Analyst Decision
Buy
Hold
Analyst Count
5
5
Target Price
$4.25
★ $59.60
AVG Volume (30 Days)
★ 6.8M
74.8K
Earning Date
11-04-2026
10-27-2026
Dividend Yield
N/A
★ 3.01%
EPS Growth
★ 51.85
6.08
EPS
N/A
★ 2.64
Revenue
$1,065,000.00
★ $41,739,000.00
Revenue This Year
$28.49
$5.22
Revenue Next Year
$44.73
$5.08
P/E Ratio
★ N/A
$21.16
Revenue Growth
N/A
★ 16.96
52 Week Low
$1.04
$35.50
52 Week High
$2.01
$60.59

Technical Indicators

Market Signals
Indicator
GERN
CAC
Relative Strength Index (RSI) 36.90 47.21
Support Level $1.08 $54.50
Resistance Level $1.26 $59.21
Average True Range (ATR) 0.04 1.24
MACD 0.01 -0.06
Stochastic Oscillator 15.00 52.91

Price Performance

Historical Comparison
GERN
CAC

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

Share on Social Networks: